---
figid: PMC2888474__nihms202963f2
figlink: /pmc/articles/PMC2888474/figure/F2/
number: FIGURE 2
caption: Genetic Alterations in Glioblastoma Occur Frequently in 3 Cellular Signaling                         Pathways.
  DNA alterations and copy number changes in the following signaling                         pathways
  are indicated in (a) receptor tyrosine kinase (RTK), RAS, and                         phosphoinositol–3–kinase
  (PI3K); (b) p53 tumor suppressor;                         and (c) retinoblastoma
  (Rb) tumor suppressor. Activating genetic alterations                         are
  shown in red. Genetic alterations that lead to a loss of function are                         indicated
  in blue. In each pathway, the altered components, the type of                         alteration,
  and the percentage of tumors carrying each alteration are shown.                         Blue
  boxes contain the total percentages of glioblastomas with alterations                         in
  at least 1 known component gene of the designated pathway. EGFR indicates                         epidermal
  growth factor receptor; MET, mesenchymal- epithelial transition                         factor;
  PDGFRA, platelet-derived growth factor receptor–A; PTEN,                         phosphatase
  and tensin homolog; . Reprinted with permission from The Cancer                         Genome
  Atlas Research Network. Comprehensive genomic characterization                         defines
  human glioblastoma genes and core pathways. Nature.                             2008;455:1061–1068.
pmcid: PMC2888474
papertitle: Exciting New Advances in Neuro-Oncology.
reftext: Erwin G. Van Meir, et al. CA Cancer J Clin. ;60(3):166-193.
pmc_ranked_result_index: '65796'
pathway_score: 0.8904514
filename: nihms202963f2.jpg
figtitle: Genetic Alterations in Glioblastoma Occur Frequently in 3 Cellular Signaling                         Pathways
year: ''
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC2888474__nihms202963f2.html
  '@type': Dataset
  description: Genetic Alterations in Glioblastoma Occur Frequently in 3 Cellular
    Signaling                         Pathways. DNA alterations and copy number changes
    in the following signaling                         pathways are indicated in (a)
    receptor tyrosine kinase (RTK), RAS, and                         phosphoinositol–3–kinase
    (PI3K); (b) p53 tumor suppressor;                         and (c) retinoblastoma
    (Rb) tumor suppressor. Activating genetic alterations                         are
    shown in red. Genetic alterations that lead to a loss of function are                         indicated
    in blue. In each pathway, the altered components, the type of                         alteration,
    and the percentage of tumors carrying each alteration are shown.                         Blue
    boxes contain the total percentages of glioblastomas with alterations                         in
    at least 1 known component gene of the designated pathway. EGFR indicates                         epidermal
    growth factor receptor; MET, mesenchymal- epithelial transition                         factor;
    PDGFRA, platelet-derived growth factor receptor–A; PTEN,                         phosphatase
    and tensin homolog; . Reprinted with permission from The Cancer                         Genome
    Atlas Research Network. Comprehensive genomic characterization                         defines
    human glioblastoma genes and core pathways. Nature.                             2008;455:1061–1068.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MDM2
  - GNAL
  - ERBB2
  - AKT2
  - CDKN2A
  - AKT1
  - PIK3R4
  - NF1
  - CDKN2C
  - AKT3
  - EGFR
  - FOXO4
  - TP53
  - FOXO3
  - CDKN2B
  - CCND2
  - NRAS
  - HRAS
  - FOXO6
  - PIK3CG
  - PIK3R5
  - MDM4
  - CDK4
  - PIK3CA
  - GNAS
  - KRAS
  - MET
  - PIK3R6
  - PTEN
  - RB1
  - FOXO1
  - PIK3CD
  - PIK3CB
  - PIK3R3
  - CDK6
  - PDGFRA
  - Cancer
  - Lung cancer
genes:
- word: MDM2
  symbol: MDM2
  source: hgnc_symbol
  hgnc_symbol: MDM2
  entrez: '4193'
- word: G1/S
  symbol: Gs
  source: bioentities_symbol
  hgnc_symbol: GNAL
  entrez: '2774'
- word: ERBB2
  symbol: ERBB2
  source: hgnc_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: (ARF)
  symbol: ARF
  source: hgnc_alias_symbol
  hgnc_symbol: CDKN2A
  entrez: '1029'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: NF-1
  symbol: NF1
  source: hgnc_symbol
  hgnc_symbol: NF1
  entrez: '4763'
- word: CDKN2C
  symbol: CDKN2C
  source: hgnc_symbol
  hgnc_symbol: CDKN2C
  entrez: '1031'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: FOXO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO4
  entrez: '4303'
- word: TP53
  symbol: TP53
  source: hgnc_symbol
  hgnc_symbol: TP53
  entrez: '7157'
- word: CDKN2A
  symbol: CDKN2A
  source: hgnc_symbol
  hgnc_symbol: CDKN2A
  entrez: '1029'
- word: FOXO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO3
  entrez: '2309'
- word: CDKN2B
  symbol: CDKN2B
  source: hgnc_symbol
  hgnc_symbol: CDKN2B
  entrez: '1030'
- word: CCND2
  symbol: CCND2
  source: hgnc_symbol
  hgnc_symbol: CCND2
  entrez: '894'
- word: RTK/RAS/PI-3K
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: RTK/RAS/PI-3K
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: FOXO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO6
  entrez: '100132074'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: MDM4
  symbol: MDM4
  source: hgnc_symbol
  hgnc_symbol: MDM4
  entrez: '4194'
- word: CDK4
  symbol: CDK4
  source: hgnc_symbol
  hgnc_symbol: CDK4
  entrez: '1019'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: G1/S
  symbol: Gs
  source: bioentities_symbol
  hgnc_symbol: GNAS
  entrez: '2778'
- word: RTK/RAS/PI-3K
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: P53
  symbol: p53
  source: hgnc_alias_symbol
  hgnc_symbol: TP53
  entrez: '7157'
- word: MET
  symbol: MET
  source: hgnc_symbol
  hgnc_symbol: MET
  entrez: '4233'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: RB1
  symbol: RB1
  source: hgnc_symbol
  hgnc_symbol: RB1
  entrez: '5925'
- word: FOXO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO1
  entrez: '2308'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: CDK6
  symbol: CDK6
  source: hgnc_symbol
  hgnc_symbol: CDK6
  entrez: '1021'
- word: PDGFRA
  symbol: PDGFRA
  source: hgnc_symbol
  hgnc_symbol: PDGFRA
  entrez: '5156'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
---
